Biogenes Technologies Sdn Bhd (Biogenes) is a Malaysian-based startup company founded in 2015. Biogenes developed aptamer-based biosensor technologies and solutions in rapid test devices in molecular diagnostics for disease testing. Biogenes’ rapid test devices are designed to serve customers from various sectors ranging from healthcare, animal breeding, aquaculture, agriculture and environmental monitoring.

In the wave of the current global pandemic, Biogenes has developed a rapid antigen test kit called COVIDSENSETM with real-time digital communication capabilities to provide location and data to the users and medical stakeholders. This test kit is able to conduct fast and efficient testing utilizing the proprietary aptamer-based technologies developed by Biogenes to detect the presence of COVID-19 Virus (SARS-COV-2) with both high selectivity and sensitivity. Biogenes unique deep tech platform allows Biogenes to add more infectious disease including MERS, SARS, TB, and other communicable and non-communicable diseases in human, animals and plants. Biogenes aims to build a library of tests which includes diseases in This will enable Biogenes to overcome the current pandemic while laying the ground work for future growth into the diagnostic sector. Biogenes wants to build simple, easily scalable and user-friendly tests for now and the future. This will be in line with Biogenes’ tagline ‘Diagnostics Simplified’

Nitium Technology just founded 4 years ago but able to bring competition to other global implant manufacturers, not to mentioned that this start-up company can produce competitive solutions with better material at lower cost. This start-up not only has developed the world’s first porous Nickel Titanium dental implant but also reduces more than 60% of average production cost. With correct business model, this advantage enables them to venture into ASEAN market and overcome the issues in dentist expertise and lack of disposable income.

While participating in niche market industry, Nitium Technology already obtained awards and recognition not only from Malaysia, but also globally such as Japan, South Korea and Germany. The start-up company is putting Japan as one important target country, not only to tap on higher disposable income market but also to partner up with Japanese companies that capable in advance materials and precision machinery.

Nitium Technology was nominated because the future of its technology in different types of implant, for example Orthopaedic and Cranial implant market, without the need to repeat pre-clinical trials to enter the markets. I believe what the company require now is financial support and technology collaboration with Japanese high-tech companies.

We create and integrate 3D depth sensing technology. 3D cameras are enabling new intelligent products across a spectrum of markets from automotive, robotics, industrial automation, consumer electronics and security. We are masters in time-of-flight depth sensing and bridge the gap from pixel to point cloud, expertly tailoring fit-for-purpose 3D solutions for our partners. We partner with silicon technology developers leveraging our 20+ patent portfolio to generate licensing revenues and work alongside customers to integrate tailored 3D camera solutions into their products.

Care Mentor AI – developer of the Computer Vision Systems for Analysis of Radiology Diagnostics.
Founded in 2018 with the ultimate goal of reducing the number of medical errors, improving diagnostic quality in general and extending life expectancy.
We create product to help Doctors to make diagnostic faster and with higher accuracy.
We have the next products which already have been probated in Russian clinics:
Screening for Pathologies on Chest Xray
Covid-19 detection on CT
As well as other products, as screening of Xray Brest on oncology and CT Oncology detection, are on the final stage of development.
All our products get Scientific publications and clinical tests to proof quality and accuracy.

Laboratory “Sensor-Tech” has been established to solve most ambitious scientific goals and create advanced technologies for people with hearing and visual impairments, including the deaf-blind, in Russia and in the world. In our work, we apply modern technologies, including AI, and develop products that empower people with sensory impairments. Nowadays, our key projects are: Smart assistant “Robin”, designed to enable blind people to better orientate themselves indoors and outdoors. “Robin” can recognize objects, people and their faces, determine distance to them and detect obstacles with the help of an ultrasonic radar. “Robin” works without Internet connection or third-party applications. Developed as a complement to a white cane, “Robin” is simple to use and does not require long training. Our other flagship product – Speech recognition device “Charly”, designed for independent communication with hearing impaired people. “Charly” recognizes speech, converts it into text and displays recognized speech on a monitor, a mobile phone, a TV, or a Braille display. “Charly” also allows to work and study remotely. Besides, we have launched Ophthalmic VR-simulator “See My World”, mobile apps “Currency note recognizer” and “Object recognizer”, implement a large genetic research in Russia and organized the first retinal implant surgeries (bionic vision) in Russia.

4Blind company conducts research, develop, create and produce innovative technologies for the rehabilitation and improvement the quality of life of blind and deaf-blind people. 4Blind technical solutions: help them to communicate; give access to information around them; help develop in the professional field.

Advantages of 4Blind solutions: multifunctionality, its suitability for various objectives such as reading, writing, communication, the use of mobile phone, tactile access to graphic information; lack of comparable analogues in the market or absence of analogues; ease of use and servicing; affordable price.

Market opportunities: according to the latest report of the WHO in the world more than 7 million deafblind and more than 285 million blind people.

Sales strategy: direct sales to support organizations and foundations for people who are blind and deaf-blind, rehabilitation centers for the deaf-blind people, public and private companies providing jobs for people with disabilities, insurance companies; sales through international distributors of technical rehabilitation equipment, as well as sale of licenses for the right to manufacture the device in other countries.

We’ve already conducted testing of devices in associations and funds engaged in the support of blind and deafblind people having received confirmation that users need them, and devices meet expectations.

JN Medsys is a Singapore biomedical company dedicated to providing super resolution genomic tools for precise and personalized diagnostics. Founded in 2010, our vision is to improve lives through advanced diagnostics in healthcare. We have been working relentlessly over the years to create cutting-edge genomic tools, comprising instruments and kits, that provide better sensitivity and accuracy for nucleic acids analysis. Through these advanced diagnostics, we hope to generate actionable insights to improve the outcomes of cancer and to eradicate infectious diseases. More recently, we have developed an end-to-end solution for Covid-19 testing. Our test is able to provide accurate, fast, and high capacity Covid-19 testing, even for countries which have limited resources.

Meracle brings relief and assurance to patients with respiratory and chronic ailments by optimizing the delivery of therapy in a safe, reliable and efficient manner, with the ultimate goal of setting the industry’s benchmarks and standards. Meracle’s first product, the Whizz, improves the management of respiratory conditions by increasing the efficiency of medication delivered into the lungs while tracking intake data to augment the assessment of treatment outcomes. Through trials we have shown that the Whizz improves technique and compliance by 100%, leading to better asthma control and reduced symptoms. The system consist of a hardware that helps deliver medication effectively to patients, paired to a mobile application that has multiple features to track and encourage compliance through gamification as well as manage treatment regimen. The data collected benefits multiple stakeholders, by first improving the quality of life of patients and helping them gain a sense of control over their situation. Doctors have access to objective data that makes it easier to target accurate prescription medication and governments are able to improve public health and reduce the burden on an overwhelmed healthcare system.